Hormones are chemical substances that our body produces in different glands and which are responsible for regulating most of our body functions.

At Neolife we’re not doing an extravagant treatment, it’s only a more advanced understanding of hormone management, which comes from our training in institutes that have spent years in this area and from our experience in these years in which we’ve treated hundreds of patients.

Dr. Iván Moreno – Neolife Medical Team

The correct functioning of hormonal axes is vital for keeping our tissues, organs and functions in optimal condition.

Replacement therapy or bioidentical hormonal optimization is one of the essential foundations of treatment at Neolife (when it is necessary and always adapted to the particular circumstances of each case).

Though it is striking and contradicts many of the prejudices we have with respect to hormones, it’s true that in the centers in the United States where we trained they have been working on this for about 25 years. Experience accumulates and the benefits of it are expanding into the scientific arena.

This week two items of news in Medscape, one of the most important medical dissemination platforms in the world, show that, far from being a radically new therapy, it is being established as a new standard which in a few years will be the usual way to prescribe hormone therapy.

• US Docs More Likely to Prescribe T3/T4 Combo Tx for Hypothyroid.
• Bioidentical Hormone Combo Improves Sleep After Menopause.

We are briefly going to review the importance of this treatment and the particular details of our approach, which as we see is that of more and more professionals.

Hormones are very important.

The correct functioning of hormonal axes is vital for keeping our tissues, organs and functions in optimal condition.

Hormones are chemical substances that our body produces in different glands and which are responsible for regulating most of our body functions.

In the case of sexual hormones, a progressive loss begins in men after the age of 40, and there is a much sharper loss in the case of women, who in the years prior to the menopause already have low levels of progesterone and testosterone and after the menopause of estradiol too.

In the case of other hormones such as melatonin, DHEA or thyroid hormone the loss of secretion is gradual due to atrophy of the gland, deregulation of the production and lesser sensitivity of the cell receptors where the hormones must bind.

Once we have reached a certain age and, in the case of sexual hormones, once we cease to be fertile, the result of the loss of hormone levels is the deterioration of all the organs in which these hormones have receptors (most of them).

The loss of the correct hormone balance alters cellular intercommunication and is one of the mechanisms of aging. Fortunately, it is one on which we can act.

Hormone replacement/optimization is safe.

The use of hormones has been subjected to a smear campaign in recent years. The fact is that this smear campaign, like many others, has some basis in truth, but not because hormones are harmful (our body wouldn’t produce a substance that is toxic or harmful to itself), but because we’ve been using without respecting two important rules:

1) You have to use the same hormone as our body had.

Our hormones are molecules designed by evolution over the course of thousands of years, which fit and do their job perfectly on cell receptors. But what we’ve been using for years and in some clinical studies in which side effects were seen are synthetic derivatives of hormones. These derivatives are substances designed in a laboratory so be sufficiently similar to the original hormone as to work, but sufficiently different to be able to be patented.

We can’t try to make them the same, but nevertheless we’ve been using hormone derivatives on the premise that “they are the same…but better”:

• “They’re the same but they can be used as a patch”
• “They’re the same but they can be impregnated in an IUD”
• “They’re the same but stronger”

Clinical studies are very costly, and the first studies that were carried out used synthetic hormones, since they have a limited patent term with results that are rushed through.

In those studies equine estrogen and progesterone derivatives were used (medroxyprogesterone) and, indeed, side effects appeared.

Bioidentical hormones (the same molecule as that which exists naturally in our body) cannot be patented, and research is much slower, in universities, with public financing, health institutes, etc. However, after almost 30 years the evidence is beginning to accumulate… And it’s as we expected: using bioidentical hormones is not the same as their derivatives.

It’s normal for us to have had side effects with those hormones, effects that in study after study do not appear with bioidentical hormones.

2) You have to reach levels that our body (in particular) had.

We are very used to taking an antibiotic or an anti-inflammatory at the same dosage for almost the entire population, making an exception only for people of very low or high weight or children.

On that same premise we’ve all thought it was normal for the dosage of a contraceptive to be standard or the dosage of a hormone therapy for the menopause to be the same for different women. When side effects appear the alternative we usually offer is to change to another pharmaceutical or cease taking it, but the dosage is not usually adjusted.

I usually use an example to help to understand the complexity and the need to adjust the dosages: insulin is a hormone and the need for different dosages for different people and the need to adjust it escapes nobody.

Using a touch of humor, I usually say to patients that the first 90% that ensures the safety and effectiveness of hormone optimization therapy is to use appropriate (bioidentical) hormones. The second 90% is to personalize the dosages. They don’t add up to 100% but nobody said medicine was simple.

At Neolife we’re not doing an extravagant treatment, it’s only a more advanced understanding of hormone management, which comes from our training in institutes that have spent years in this area and from our experience in these years in which we’ve treated hundreds of patients.

As the scientific evidence accumulates, this way of doing things will be extended until it becomes a common practice.

The specific examples

At the outset we discussed two news stories that put these ideas we’ve discussed into perspective.

The first of them “US Docs More Likely to Prescribe T3/T4 Combo Tx for Hypothyroid.” illustrates the concept of how to manage the thyroid axis has changed to conform more closely to recent evidence. It shows the need to replace the two hormones that our body has T4 (levothyroxine, circulating form) and T3 (tri-iodothyroxine, most active form) and not only T4, which is what is traditionally done.

There are numerous studies that show that replacing only one of the two hormones causes a partial correction of the problem, not helping with the correct functioning of metabolism, weight and cholesterol correction and recovery of the typical lack of energy that appears in hypothyroidism.

And not only do studies support it, we have many cases in which, by simply changing levothyroxine for a combination of the two, the life of the patients has completely changed.

Traditionally, it has been explained to us that upon replacing T4 it would be automatically converted into T3, but the fact is that there are many factors that determine this: stress, being on a slimming diet, pollution, some people have a lower conversion rate… there are many reasons why replacement with only T4 does not work.

In the USA, this approach, which until recently was controversial is being used more widely and before long nobody will consider replacing thyroid metabolism with half the hormones that our body had.

The second news story “Bioidentical Hormone Combo Improves Sleep After Menopause” shows how the concept of bioidentical hormone, insofar as it has different benefits and risks than a synthetic hormone derivative, is no longer a manner of speaking for alternative doctors but rather the medical community is accepting the scientific evidence and changing the paradigm of “all hormones are equal”.

In this case they show that the use of estradiol and progesterone, the same as our body had prior to the menopause, improve one of its symptoms: insomnia or the loss of sleep quality.

In this case the improvement comes from the disappearance of hot flashes, both with estradiol and with progesterone and due to the sedative and relaxing effect of progesterone.

Again the difference is enormous, therapy with estradiol and progesterone has shown that it eliminates most of the mood disorders that appear in the peri/menopause and cause wellbeing, but progesterone derivatives do not have those benefits and there are even recorded cases of depression and suicidal ideation.

Progesterone does not cause breast cancer, in fact there are studies with women who already have that cancer in which progesterone is used as a treatment against breast cancer. However, progesterone derivatives cause an increase in breast cancer, all of them to a greater or lesser extent.

Progesterone derivatives are responsible for our associating hormones with more coagulates, but progesterone is not associated with more coagulates.

And that goes for so many other side effects. Bioidentical hormone optimization is not risk-free, and it must be done properly, but it does not increase the presence of cancer, thrombosis and heart attacks.

We understand that this advanced approach clashes with beliefs and prejudices of patients and of other professionals, and we teach in order explain why we do what we do. We firmly believe that this gives our patients security and allays the concerns of the other doctors who treat them for other pathologies.

What we do is based on an experienced interpretation of the scientific evidence, but it is firmly established in it.

At Neolife we carry out hormone optimization after a careful assessment of the imbalances present, choosing bioidentical hormones and using analyses and symptoms to adjust the treatments as precisely as possible to the specific needs of each patient.

BIBLIOGRAPHY

(1) https://www.medscape.com/viewarticle/907416 nlid=127097_2043&src=WNL_mdplsnews_190111_mscpedit_obgy&uac=286768PK&spon=16&impID=1857724&faf=1#vp_2

(2) https://www.medscape.com/viewarticle/907360?nlid=127097_2043&src=WNL_mdplsnews_190111_mscpedit_obgy&uac=286768PK&spon=16&impID=1857724&faf=1

(3) Campagnoli C, Clavel-Chapelon F, steroid RKTJO, 2005. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. Elsevier.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974841/

(4) Tariq A, Wert Y, Cheriyath P, Joshi R. Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life. Southern Medical Journal. 2018 Jun;111(6):363–9.

La entrada When what was extravagant becomes a common practice se publicó primero en Neolife.

A study has shown that hypothyroidism, even at a subclinical level, is associated with an increased occurrence of sudden death events and overall mortality.

The reason for hypothyroidism being associated with such an increase in mortality could be due to the worsening of the lipid profile and endothelial dysfunction. Such factors would therefore promote the formation of atheromatous plaques within the artery walls, which could contribute to the incidence of ischemic strokes and heart attacks.

Dr. Moisés De Vicente – Neolife Medical Team

A recent study published in the journal Clinical Endocrinology conducts a review between the association of thyroid dysfunction and sudden cardiac death.

The thyroid is a key gland in our metabolism. It is responsible for the production of the thyroid hormone, primarily in the form of T4, and to a lesser extent T3, although in fact it is this latter type of thyroid hormone that is truly active at a cellular level. As a method of regulation, the thyroid-stimulating hormone, TSH, secreted at the pituitary level, stimulates T4 and T3 production depending on the blood levels of these two thyroid hormones. If these levels fall, TSH is increased so as to stimulate their production, and vice versa.

There are several functions of thyroid hormones, which act at the level of most of our organs and systems. We could say that these are global hormones that help to optimize our cellular metabolism, in addition to many other important actions.

Nowadays, the management and treatment of thyroid dysfunctions is beginning to change, making obsolete many of the paradigms under which much of conventional medicine is taught (this subject has already been addressed in our blog under the title: Are we wrong about the thyroid? (Sep 2017).

At Neolife, we are at the forefront of bioidentical hormone treatment, among which thyroid hormone therapy is included. We are not satisfied with merely maintaining TSH levels within normal range or maintaining a wait-and-see approach towards subclinical hypothyroidism. We go further, and aim to “set” our T3 values (remember, the active hormone) within the optimum range.

Why do we do this? Because we are firm defenders of the optimization of our cells and organs, and current literature on the matter confirms that having an excellent thyroid leads to enjoying an excellent life.

The way thyroid function affects, directly or indirectly, the cardiovascular system is something that has been studied previously. Frank hypothyroidism and even subclinical hypothyroidism have been linked to the incidence of various cardiovascular risk factors such as dyslipidemia, arterial stiffness and endothelial dysfunction (1). It has also been argued that an incidence of hypothyroidism predisposes to the onset of sudden cardiac death and increases the risk of presenting cardiac arrhythmias, and atrial fibrillation in particular (2).

The dispute over whether this relationship leads to an increased cardiovascular risk and if, therefore, such patients should be medicated to regulate their thyroid function, is still a burning issue. With this in mind, the journal Clinical Endocrinology(3) has published a review between the association of thyroid dysfunction and sudden cardiac death.

More than 5,000 patients over the age of 30 were included, with follow-ups over the course of 13 years. The relationship between thyroid dysfunction (either due to the presence of hyper- or hypothyroidism of any magnitude) was assessed in association with overall mortality, sudden cardiac death, and the incidence of cardiovascular diseases and atrial fibrillation.

Researchers have shown that the existence of hypothyroidism, even at a subclinical level, is associated with the occurrence of more sudden cardiac deaths, thus signifying an increase in overall mortality. Likewise, the presence of TSH levels towards the higher normal limit was not associated with an increase in the incidence of atrial fibrillation or cardiac arrhythmias.

The reason why hypothyroidism is associated with an increase in mortality is something that needs to be confirmed by further studies. It is hypothesized that the worsening of the lipid profile and endothelial dysfunction play a role in this process, but mainly with regard to an increase in cardiovascular diseases. Such factors would therefore promote the formation of atheromatous plaques within the artery walls, which could contribute to the incidence of ischemic strokes and heart attacks.

What other mechanisms explain these results? It has been described how hypothyroidism causes an increase in silent inflammation (highlighted by an increase in C-reactive protein or CRP) and cellular oxidative stress, among others. These two processes involve damage to the base level of cells which, in the long term, is very likely to produce an acceleration in cell aging, eventually leading to organic dysfunction. However, although these are two examples of how thyroid hypofunction can generate this increase in mortality, regardless of the increase in cardiovascular risk, there are still many grey areas ripe with a lack of verified knowledge.

At Neolife, we perform an optimization of thyroid function of our patients, so as to reach optimum conditions. We seek to set active thyroid hormone levels to the higher end of the normal range, in order to achieve perfect activity at a cellular level. With this, not only will we achieve a reduced cardiovascular risk, but also the perfect functionality of our body, improving our quality of life and feeling of well-being

BIBLIOGRAPHY

(1) Cooper DS, Biondi B. Subclinical thyroid disease.  2012; 379:1142–1154.

(2) Jabbar A, Pingitore A, Pearce SHS, et al. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2016;14:1–17.

(3) Ville L. Langén; Teemu J. Niiranen; Pauli Puukka; Arttu O. Lehtonen; Jussi A. Hernesniemi; Jouko Sundvall; Veikko Salomaa; Antti M. Jula. Thyroid-Stimulating Hormone and Risk of Sudden Cardiac Death, Total Mortality and Cardiovascular Morbidity. Clin Endocrinol. 2018;88(1):105-113.

La entrada Is the thyroid a cardiovascular protector? se publicó primero en Neolife.

At present, medicine is based upon the control of thyroid function of the known TSH, but that is not quite accurate.

The recent scientific evidence suggests that conventional medicine is unable to efficiently manage the thyroid and that treatment should not only lower the TSH but also maintain stable levels and a high level of excellence in T4 and T3, which is often forgotten.

Dr. Francisco Martínez Peñalver – Medical Director Neolife Marbella

Preventive medicine included within the comprehensive approach in hormone replacement provides control of thyroid function with a mixture of T4/T3.

Historically, physicians have inherited a wide range of knowledge from their teachers as a basis upon which they then build their clinical practice. One of these pillars is the management of thyroid pathology, which is more and more present in our modern-day environment. 95% of thyroid disorders in adults occur in women, so there are many who believe that disorders in the menstrual cycle can, in some way, contribute to the thyroid losing functionality in a progressive way.

The knowledge traditionally passed on by our teachers advocates that the hormone level is controlled in the anterior of the brain, in a small stem called the pituitary. This hormone is known as TSH, and is a mechanism to control the thyroid, since at lower circulating levels of T3 and T4 the level of TSH secretion is higher, which is the hormone that stimulates the thyroid to produce more of the hormone. Traditionally the control of TSH was assumed to have been conducted through the thyroid.

However, the pituitary-thyroid axis a crucial element has been disregarded considering the transformation in the peripheral tissues from T4 to T3, something that is fundamental for the hormone to work.

In recent years the concept that the transformation which takes place in peripheral tissues to active hormones may be even more important than the control that TSH exerts on the thyroid gland is gradually being formed. Numerous articles, as far back as 2010 have stated this position. From the “Clinical Endocrinology of Oxford” about the effectiveness of adding T3 in those patients with a controlled thyroid function as a means to increase their cognitive capacity; to the latest article last April in the “Innovations in Clinical Neuroscience” journal which speaks openly about how controlling T3 levels is crucial for some symptoms associated with low thyroid function, such as depression and weight gain.

In summary, the recent scientific evidence suggests that conventional medicine is unable to efficiently manage the thyroid and that treatment should not only lower the TSH but also maintain stable levels and a high level of excellence in T4 and T3, which is often forgotten. This may be the answer to many patients who suffer the symptoms of poor thyroid control, but who are labelled as “free-from thyroid disease” because the usual clinical practice only addresses TSH levels.

The Neolife preventive medicine clinic with our comprehensive approach to hormone replacement using bioidentical hormones aims to provide the ideal hormonal profile for every patient thanks to the hormones that have been used for years to control thyroid function along with the T4/T3 mixture.

BIBLIOGRAPHY

(1)

La entrada Are we wrong about the thyroid? se publicó primero en Neolife.

Both candidates for the White House, Hillary Clinton and Donald Trump have presented tests and prescriptions used in Age Management Medicine.

Following the recent health problems with the Democratic candidate, both aspiring US Presidents have shown that they use preventive anti-ageing medicine as part of their personal health regime: calcium scoring, thyroid function assessment, chest x-ray, resting electrocardiogram, body mass index, supplementation using Armour Thyroid and vitamin B12 etc. represent just some of the parallels we have observed with medicine that we practice at the Neolife clinic.

Neolife medical management

The candidate for the President of the United States Hillary Clinton subjects herself to Calcium Scoring and takes Armour Thyroid, two key elements in Preventive Anti-ageing Medicine.

During the past weeks there has been widespread media hype about the health of the prospective presidential candidates, Hillary Clinton and Donald Trump, following the recent public illness of the former during the commemorative events surrounding 9/11. A few hours after this event, the offices for both candidates rushed to disclose their medical data to evidence the health and suitability of each to hold such high office within American politics. On the one hand, Dr. Bardack, a New York internist and Hillary Clinton’s personal physician, presented a two-page document. On the other, Donald Trump discussed his health live on the famous Dr. Oz program by referencing data provided by his doctor, Dr. Borstein, a gastroenterologist from New York.

Regardless of the fact that Hillary Clinton, 68 suffered an illness of some sort in public the document confirmed that she was suffering from an acute episode of pneumonia which was being treated with an antibiotic and that her health was otherwise good. Her calcium score, amount of calcium in her coronary arteries is stated to be “zero”, that is to say, there is no calcified plaque in the coronary arteries, which is considered very good news from the point of view of cardiovascular health.

The candidate takes:

• Armor Thyroid, a combination of thyroid hormones T4 and T3 to treat underactive thyroid function.
• Coumadin, an anticoagulant, due to a history of thromboembolisms after a cranial trauma in 2012.
• Clarinex when required, an antihistamine for episodes involving her allergies.
• Vitamin B12.

In view of the limited nature of the medical data disclosed, we have noticed some parallels with our tests and prescriptions that we provide at Neolife.

The determination of a calcium score is one of the routine cardiovascular prevention tests we carry out at Neolife. This is probably the most important test to undergo in the prevention of myocardial infarctions, for those in the high risk band of cardiovascular risk factors according to the Framingham formula. Measuring your cardiovascular risk according to your age, sex, total cholesterol, HDL (good) cholesterol, blood pressure, whether you smoke or not and whether you are currently taking any antihypertensive drugs is a crude way to predict whether or not you have atheromatous plaque. Even more so when a simple short test that is not invasive with minimal risk of radiation can allow you to see whether or not there is atheromatous plaque and put aside presumptions and conjecture about atheromatous plaque. This is the reason why most of our patients know whether or not they have plaque prior to determining other coronary risk factors. It is important to note that one third of deaths from acute myocardial infarctions occur in patients who have never previously presented symptoms or signs of coronary heart disease. These deaths may have been preventable if the plaque had been noted prior to the fatal event.

On the other hand, Mrs Clinton is taking Armour Thyroid, one of the “leading” therapies provided as part of Age Management Medicine in the USA. Armour Thyroid is a combination of two thyroid hormones, T4 and T3 which uses an approximate 80/20% ratio. There are no such combination treatments available in Spain: the treatment of hypothyroidism is completed solely using T4. However, numerous studies have demonstrated improved clinical results when T4 is combined with T3. In addition, as the Clinton medical report states, she is taking Armour, not because she has hypothyroidism, but an underactive thyroid. That is to say, the symptoms do not meet the diagnostic criteria for hypothyroidism, but she continues to suffer the symptoms associated with a thyroid gland deficiency. In Age Management Medicine this is treated and not allowed to develop, in essence to prevent suffering. Yet, the patient cannot be treated until the analysis has been completed… Some of our patients receive a prescription for Armour Thyroid in the US, but the majority who need this combination of thyroid hormones are prescribed a master compound.

The Republican candidate Donald Trump also assesses the biomarkers that are conventionally used in Age Management Medicine, such as calcium scoring, chest x-rays, resting electrocardiogram and BMI (Body Mass Index).

In the case of Trump (70 years old), the report provided by his doctor, Dr. Borstein included the following information:

• His calcium score is 98, which confirms that he has atheromatous plaque, although in a mild-moderate amount. A score value of 0-10 is considered as mild atherosclerosis, up to 100 is mild-moderate, up to 400 is moderate, up to 1000 is significant and above 1000 is referred to as the “Oh my God zone” (oh, my God!).
• His cholesterol and thyroid function are normal as well as the results from his prostate exam and colonoscopy carried out in 2013.
• Trump currently weighs 107 kg and is 190 cm tall, which implies a BMI of 29.6, that is to say he is considered to be within the overweight type 2 or preobesity category.
• His chest x-ray and resting electrocardiogram are normal.
• Donald Trump plays golf, but lately his physical activity is principally connected to his electoral campaign, which is considerable.
• He is treated with rosuvastatin, a medication to control cholesterol and ensure that your arteriosclerosis plaque remains stable, that is to stay, prevent the plaque from growing.

Again the data provided by Trump’s doctor is often provided to patients at the Neolife clinic.

In light of the limited data from both candidates it would appear that Hillary Clinton is in better health than her opponent, particularly in terms of cardiovascular health. And we must not forget that cardiovascular disease is the leading cause of death in developed countries.

La entrada Clinton, Trump and Neolife, the presidents of medicine se publicó primero en Neolife.

A recent study has stated that people with subclinical hypothyroidism are almost twice as likely to have diabetes.

The study analyzed patients and noted that those with a TSH of 4 mIU/L had a 35% greater chance of developing diabetes than those with a TSH of 0.4 mIU/L (who had only a 19% chance). Although the authors are not fully aware of the intimate mechanism or reason for this association, the hypofunction of thyroid hormones would appear to have a direct impact on the development of prediabetes and diabetes.

Neolife medical management

Subclinical disease, a key phase in the prevention of diseases such as hypertension, diabetes or hypothyroidism.

The approach taken in relation to the disease during the subclinical phase is one of the principal objectives of the MP4 (Preventive, Proactive, Predictive and Personalized Medicine) or Age Management Medicine approach. The subclinical phase is the phase in which the disease has not yet developed into symptoms or signs that may help us classify the disease as such; it is a grey area where you have a disease but do not have any symptoms. But we all know, using simple logic and common sense, that many diseases can not be defined by an arbitrary red line drawn by a human. For example, the definition of hypertensive is when the systolic blood pressure exceeds 140 mmHg and/or the diastolic pressure exceeds 90 mmHg; so if my blood pressure is 135/85 mmHg, I am not hypertensive. You are diabetic if your fasting glucose is more than 126 mg/dL; so if I have a fasting glucose of 120 mg/dL, I am not diabetic. You have a hypothyroid if your TSH (thyroid stimulating hormone) is above 10 mIU/L; so if my TSH is 3.7 mUI/L, I do not have a hypothyroid. But the reality is that in the three examples above I could be pre-hypertensive, pre-diabetic and have a sub-clinical hypothyroid. And here is the key to MP4: take action at this crucial phase in the disease, before it is too late.

Thyroid function tests consist of a group of key biomarkers in our protocols. These biomarkers are TSH (thyrotropin: thyroid-stimulating hormone), free T4 (thyroxine) and free T3 (triiodothyronine). According to the ATA (American Thyroid Association), the possible causes of hypothyroidism include: congenital defects or autoimmune diseases, total or partial surgical resection of the thyroid gland, radioactive treatment, inflammation (thyroiditis), iodine deficiency or excess iodine in the diet, a side effect of some medication or damage to the brain localized in the pituitary gland. However, there is another cause: our own ageing.

A recent study has confirmed that there is a correlation between subclinical hypothyroidism and an increased likelihood of developing prediabetes and diabetes.

The endocrine function of most of our glands deteriorates with the passage of time: this is part of the programmed senescence (aging). Like testosterone plasma levels, the growth hormone or estradiol decline with age (and time) and the same takes place with the thyroid hormones, although to a lesser extent. The reality remains that as we age our thyroid function lowers in the thyroid gland (especially in women) which could be defined as evidence of sub-clinical hypothyroidism. This is particularly true when combined with slightly elevated TSH values, but normal free T4 and free T3 values, as well as non-specific symptoms including fatigue, weight gain, coldness, capillary fragility, dry skin, etc.

A recent study presented a month ago at the annual Endocrine Society Conference (ENDO 2016) held in the Netherlands (1) has confirmed the correlation between subclinical hypothyroidism and an increased likelihood of developing prediabetes and diabetes. The study assessed 8,452 people over 45 who lived in Rotterdam. Over the course of approximately 8 years, 1,100 of them developed prediabetes and 798 developed diabetes. When their TSH values were analyzed it was found that those with a TSH level of 4 mIU/L had a 35% chance of developing diabetes compared to those with a TSH level of 0.4 mIU/L who had only a 19% chance of developing the condition. The authors do not fully understand the intimate mechanism or reasons behind this association, but have stressed that given that thyroid hormones are important as part of the normal energy metabolism and for proper weight control, their hypofunction could have a direct impact on the development of prediabetes and diabetes.

Hormonal and metabolic optimization is one of the pillars of the Neolife anti-ageing medical programs. What nature denies us through programmed senescence (aging), we can safely restore thanks to hormone replacement therapy with bioidentical hormones. An optimization of thyroid function will not only improve symptoms such as tiredness, weight gain, dry skin and brittle hair but also help protect us from diabetes and cardiovascular disease.

BIBLIOGRAPHY

(1) “Thyroid Function and Type 2 Diabetes Risk: A Population-Based Prospective Cohort Study”. ENDO 2016; April 3, 2016; Boston, Massachusetts. Abstract OR33-2.

https://endo.confex.com/endo/2016endo/webprogram/Paper24901.html

La entrada Subclinical hypothyroidism may encourage type 2 diabetes se publicó primero en Neolife.